Send us Feedback

Candela (CLZR)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

CLZR » Topics » Compensation Committee Report

These excerpts taken from the CLZR 10-K filed Oct 27, 2008.

Compensation Committee Report

 

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management, and based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.

 

Douglas W. Scott

George A. Abe

Nancy E. Nager

 

11


Compensation
Committee Report



 



The
Compensation Committee has reviewed and discussed the Compensation Discussion
and Analysis required by Item 402(b) of Regulation S-K with management,
and based on such review and discussions, the Compensation Committee
recommended to the Board of Directors that the Compensation Discussion and
Analysis be included in this Annual Report on Form 10-K.



 



Douglas
W. Scott



George
A. Abe



Nancy
E. Nager



 



11













This excerpt taken from the CLZR DEF 14A filed Oct 29, 2007.

Compensation Committee Report

        The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management, and based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and the Company's annual report on Form 10-K.

                        Douglas W. Scott
                        George A. Abe
                        Nancy E. Nager

15

EXCERPTS ON THIS PAGE:

10-K (2 sections)
Oct 27, 2008
DEF 14A
Oct 29, 2007

RELATED TOPICS for CLZR:

"Compensation Committee Report" elsewhere:

The Aristotle (ARTL)
Aspect Medical Systems (ASPM)
ATS Medical (ATSI)
Avigen (AVGN)
Advancis Pharmaceutical (AVNC)
Avalon Pharmaceuticals (AVRX)
Biopure (BPUR)
Cell Genesys (CEGE)
CollaGenex Pharmaceuticals (CGPI)
Clinical Data (CLDA)
Criticare Systems (CMD)
Continucare (CNU)
Caraco Pharmaceutical Laboratories (CPD)
CuraGen (CRGN)
Zalicus Inc. (CRXX)
Cardiac Science (CSCX)
Diversa (DVSA)
Eclipsys (ECLP)
Ev3 (EVVV)
PC GROUP, INC. (GAIT)
Fibrocell Science, Inc. (ILE)
GALECTIN THERAPEUTICS INC (PRW)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki